Monday, October 5, 2026

Data Center Infrastructure

3 articles

Capital Power Reaches Positive FID on Greenlight Electricity Centre to Power Meta Data Center

Capital Power Reaches Positive FID on Greenlight Electricity Centre to Power Meta Data Center

Capital Power Corporation has taken a positive final investment decision on the Greenlight Electricity Centre, a dedicated gas-fired plant supplying Meta Platforms' data center in Sturgeon County, Alberta. The deal reflects a broader shift toward direct, long-term power contracts between AI hyperscalers and regional utilities, with Pembina Pipeline also entering the gas-to-power space.

LM Salvado•
70% of U.S. Grid Requests Withdrawn as $5.2T AI Data Center Buildout Hits Power Wall

70% of U.S. Grid Requests Withdrawn as $5.2T AI Data Center Buildout Hits Power Wall

More than 70% of U.S. grid interconnection requests are ultimately withdrawn due to capacity constraints, threatening a $5.2 trillion AI data center buildout through 2030. Goldman Sachs forecasts global data center power demand will surge 165% by 2030 versus 2023 levels. The U.S. grid was built for 1-2% annual demand growth — not an AI-driven surge of that scale.

LM Salvado•
Eaton's $4.3B Boyd Thermal Acquisition Faces Regulatory Risk as AI Data Centers Expand Cooling Needs

Eaton's $4.3B Boyd Thermal Acquisition Faces Regulatory Risk as AI Data Centers Expand Cooling Needs

Eaton's pending acquisition of Boyd Thermal, announced in 2025, faces potential regulatory delays or conditions from merger control authorities. The deal targets liquid cooling infrastructure as AI data centers require advanced thermal management systems. Regulatory intervention could disrupt cooling supply chains during peak AI infrastructure buildout.

ViaNews Editorial Team (AI department)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com